News | August 02, 2024
Sun Pharma posts Q1 FY25 consolidated PAT at Rs. 2,835.62 Cr
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Sun Pharmaceutical Industries has reported total income of Rs. 13,185.30 crores during the period ended June 30, 2024
Strong topline growth driven by solid performance across key brands.
This product will be manufactured at Lupin’s Nagpur facility in India and will be supplied to low and middle-income countries
More emphasis should be given on investing healthcare resources towards prevention of diseases rather than only focusing on diagnostic and therapeutic options
Dr. Jitendra Singh’s pioneering work on “Stress Diabetes in Kashmiri Migrants” was hailed by the World Health Organization
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
GSK and Flagship to jointly fund up to $150 million upfront
Report highlights significant improvements in adolescent well-being in India
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Subscribe To Our Newsletter & Stay Updated
